INTRODUCTION AND OBJECTIVES: A potential risk of significant competing causes of mortality in men submitted to salvage radiation therapy (SRT) might be present. We aimed at reporting the natural history of patients treated with SRT from a large multiinstitutional series.
INTRODUCTION AND OBJECTIVES: A potential risk of significant competing causes of mortality in men submitted to salvage radiation therapy (SRT) might be present. We aimed at reporting the natural history of patients treated with SRT from a large multiinstitutional series.
METHODS: The study included 715 patients who received SRT at six tertiary referral centres for either PSA rising after RP, or PSA persistence after surgery that was defined as PSA level !0.1 ng/ml at 1 month after surgery. The irradiation of the pelvic lymph nodes area was left at the discretion of the treating physician. The study outcomes were cancer-specific (CSM) and other cause mortality (OCM). Cox regression analyses were used to predict the risk of CSM and OCM. Predictors consisted of patient age, pT stage ( pT3a vs. !pT3b), pathologic Gleason ( 7 vs. !8), surgical margins (negative vs. positive), PSA level at SRT, and concomitant hormonal therapy (HT) administration. Competing-risks Poisson regression methodologies were performed.
RESULTS: Median patient age and PSA level at SRT were 66 years and 0.30 ng/ml, respectively. At a median follow-up of 102 months (inter-quartile range: 61, 135), local recurrence was detected in 14 (2.0%) patients, whereas 30 (4.3%), 16 (2.3%), 64 (9.2%), and 13 (1.9%) developed pelvic, retroperitoneal, skeletal, and visceral metastasis, respectively. Overall, 154 patients were died at last follow-up: 39 patients succumbed to prostate cancer, and 115 died from other cause. At 10 years follow-up, CSM and OCM rates were 13% and 37%, respectively. At multivariable competing-risks regression analyses, pathologic stage !pT3b (HR: 3.16, p¼0.006) and Gleason score ¼8 (HR: 3.56, p¼0.003) were independent predictors of CSM, after accounting for the risk of dying from other cause. Conversely, age (HR: 1.08, p<0.0001) and concomitant HT (HR: 1.15, p¼0.001) represented independent predictors of OCM, after accounting for the risk of dying from prostate cancer. When patients were stratified by age ( 65 vs. >65), the risk of OCM at 10 years was significantly higher in older patients (77% vs. 50%, p<0.0001).
CONCLUSIONS: This is the first study assessing the long-term natural history of SRT after accounting for the risk of OCM. We showed that roughly a third of men submitted to SRT died from other cause rather than from PCa and this rate increased in older men receiving concomitant HT. These results should be taken into account when deciding on the use of SRT after radical prostatectomy according to each patient profile in order to avoid potential overtreatment. 
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INTRODUCTION AND OBJECTIVES:
The role of postprostatectomy radiation therapy (RT) in patients with pN1 prostate cancer is still under debate. However, whether adjuvant RT (aRT) is equal to early salvage RT (esRT) at long term in this setting is still unknown. In this study, we aimed at comparing the long-term effectiveness of aRT versus esRT.
METHODS: Using a multi-institutional cohort from six tertiary referral centres, we identified 171 pN1 patients who were treated with radical prostatectomy and pelvic lymph node dissection. Patients were stratified into two groups: aRT (Group 1) versus initial observation followed by esRT in case of PSA relapse (Group 2). Specifically, aRT was administered at undetectable PSA level within 6 months after RP, whereas esRT was administered at a PSA level 0.5 ng/ml. The clinical target volume included the pelvic lymph nodes area, prostatic and seminal vesicle bed in all patients receiving RT. The evaluated outcomes were metastasis-free and overall survival. Multivariable Cox regression analyses tested the association between groups (aRT vs. observation AE esRT) and the study outcomes. Covariates consisted of pathologic stage ( pT3a vs. !pT3b), pathologic Gleason score ( 7 vs. !8), and surgical margin status (negative vs. positive).
RESULTS: Overall, 85 (50%) and 86 (50%) patients underwent aRT and initial observation, respectively. Median follow-up was similar among groups: 84 vs. 92 months (p¼0.9). In group 2, 69 (80%) patients experienced PSA relapse and underwent esRT. Patients characteristics were not significantly different in terms of pathologic stage (!pT3b: 60% vs. 53%, p¼0.2), Gleason score (!8: 44% vs. 41%, p¼0.9), and positive surgical margins (59% vs. 55%, p¼0.6). Overall, 26 patients developed distant metastasis with the following distribution: retroperitoneal nodes (n¼5), bone (n¼19), and other organs (n¼2). At last follow-up, 13 patients succumb to prostate cancer and 13 patients died for other cause. Metastasis-free survival (67% vs. 72% p¼0.2) and overall survival (78% vs. 74%, p¼0.8) at 8 years after RP were not significantly different among groups. These results were confirmed at multivariable analyses for both distant metastasis (HR: 0.77; p¼0.7) and overall survival (HR: 1.94; p¼0.3).
CONCLUSIONS: At long-term follow-up, timely administration of esRT showed comparable metastasis-free and overall survival to aRT. Even in pN1 patients, esRT may not thus compromise cancer control, while significantly reducing potential over-treatment associated with aRT. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1363
